QualityStocks would like to highlight InspireMD (OTCBB: NSPR), a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.
In the company’s news yesterday,
InspireMD said that it has completed enrollment in its MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial testing its stent platform technology for use in patients with Acute Myocardial Infarctions. The completion of enrollment has been achieved one month ahead of schedule, according to the company.
The MASTER Trial is a multinational randomized controlled trial being conducted in 50 centers across nine countries (Germany, Hungary, Israel, Poland, Czech Republic, France, Ireland, Brazil, and South Africa) designed to evaluate the MGuard™ and MGuard Prime Coronary Stents compared with the standard of care, bare metal stents (BMS), or drug eluting stents (DES) for acute ST-elevation myocardial infarction (STEMI) patients. The trial has enrolled 432 patients in a two-arm, parallel design study.
The primary endpoint is complete ST segment resolution. Clinical follow-up will continue for one year and important secondary endpoints such as TIMI (Thrombolysis In Myocardial Infarction) flow, MBG (Myocardial Blush Grade) and MACE (Major Adverse Cardiac Events) will be measured. Sub-studies include infarct size measured by cardiac MRI, as well as restenosis by invasive angiographic follow-up at 13 months.
The company is on track to release preliminary top line results in the third quarter of 2012.
One week ago, the InspireMD reported positive three-year results from the extended follow-up MAGICAL trial, a prospective, single arm, multi-center study conducted in 2008-09 that enrolled 60 STEMI patients, at a company-sponsored symposium at the EuroPCR conference in Paris. In that report, the company detailed that the safety and efficacy of MGuard™ observed in the trial were maintained for three years.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.